TUDRIQEV
Aug 14, 2026
Replimune Strengthens Oncology Portfolio With TUDRIQEV Approval
Summary On August 6, 2026, the FDA granted accelerated approval to Replimune’s TUDRIQEV (vusolimogene oderparepvec-wtpg), formerly known as RP1, in combination with Bristol Myers Squibb’s OPDIVO (nivolumab). The therapy is indicated for adults with unresectable, advanced cutaneous melanoma whose disease has ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
